anti-doping is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Updated 2025-11-04. Numbers and descriptions here follow the published literature rather than marketing material.
Research interest in AOD-9604 often focuses on whether it can influence lipid metabolism without the growth-promoting or glucose-related effects of full-length hGH. This question remains unresolved, and findings depend on model, dose, and measurement method. Some reviews treat the peptide as a historical obesity candidate rather than an active therapeutic. Others cite it in discussions of peptide fragments, metabolic signaling, and performance-enhancing substances. Clear conclusions are limited by the small number of rigorous, independent human studies.
AOD-9604 has been investigated primarily as a potential treatment for obesity and related metabolic conditions. Early laboratory work examined its effects on fat cells, and later studies moved into animal models and human clinical trials. Some trials reportedly reached Phase II, but the program did not lead to an approved medicine. Published summaries often note that weight-loss results were modest or inconsistent. The full trial data are not all publicly available in detail.
The peptide is frequently described as a growth hormone fragment, although it is chemically distinct from full-length hGH. AOD-9604 contains 16 amino acids and includes two cysteine residues that can form an intramolecular disulfide bond. In solution, this structural feature can influence folding, aggregation, and stability. Published descriptions sometimes call it hGH 176-191 or AOD9604, with spacing and capitalization varying. Such naming differences can complicate literature searches, database entries, and product verification.
Researchers have studied the fragment in cell and animal models to understand its metabolic actions. Some experiments report effects on fat breakdown and fat storage pathways, but the underlying mechanism remains incompletely defined. AOD-9604 does not appear to stimulate the same broad growth hormone receptor signaling as full-length hGH. Whether its observed activities arise from direct receptor interactions or downstream metabolic changes is an open question. Results from different assays are not always consistent.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to residues 176-191 of the 191-amino-acid hGH sequence. The fragment is not the full hormone and lacks the receptor-binding region associated with growth and metabolic effects of hGH. Researchers developed it to isolate a specific portion of hGH for study. Its exact sequence and length are often stated in peptide catalogs and patents.
| Property | Value | Notes |
|---|---|---|
| Primary research area | Obesity and metabolic regulation | Studied in cell, animal, and human models |
| Highest reported trial phase | Phase II | Public summaries describe mixed results |
| Common route in trials | Subcutaneous injection | Typical for peptide therapeutics |
| Regulatory example | 2013 Australian anti-doping review | Classification was debated at the time |
| Approval status | Not approved as a human medicine | Status can change by jurisdiction |
Commercial AOD-9604 may vary in purity, counterion content, and residual moisture. Certificates of analysis often report HPLC purity, mass confirmation, and appearance, but testing methods differ between suppliers. Independent verification is sometimes used because labeled content may not match actual peptide amount. Stability under different pH and temperature conditions is not fully standardized across studies. Researchers generally treat lyophilized material as the reference form for weighing and reconstitution. Moisture content can affect accurate mass measurement.
AOD-9604 is typically supplied as a lyophilized white to off-white powder. In this form, it is relatively stable when kept cool, dry, and protected from light. Common storage recommendations place it at −20 °C or below for long-term retention. Reconstituted solutions are less stable and are often kept at 2–8 °C for short periods. Freeze-thaw cycles should be minimized because they can promote aggregation or loss of peptide content. Vials are usually sealed under inert gas to reduce oxidation.
AOD-9604 drew attention in the 1990s and 2000s as a potential anti-obesity agent. Early work explored both injectable and oral routes, which is unusual for a peptide of this size. Animal studies reported changes in fat metabolism without the growth-promoting or insulin-like effects associated with full-length growth hormone. Subsequent human trials produced mixed or modest results, and the compound did not obtain regulatory approval for weight management in major markets. It remains known mainly through research literature, sports anti-doping listings, and non-approved supplement advertising.
AOD-9604 is prohibited in sport by the World Anti-Doping Agency under the peptide hormone class. Its presence in a sample can be detected through mass spectrometry-based methods, although the exact assay depends on the laboratory. In research settings, material is often supplied as a lyophilized powder for reconstitution. Buyers and researchers should note that products labeled AOD-9604 may vary in purity and actual peptide content. Analytical certificates and independent testing are common ways to verify identity, but no global harmonized standard exists for all commercial lots.
Regulatory treatment of AOD-9604 is shaped by its classification as a peptide hormone. The World Anti-Doping Agency lists it as a prohibited substance, and many national anti-doping organizations adopt that list. It does not hold approval as a prescription medicine in the United States, the European Union, or other major markets. Products sold online are frequently labeled for research use only and may not undergo independent quality testing. Import and possession rules differ by country, so legal status depends on local law.
Proposed mechanisms for AOD-9604 focus on fat cells. Laboratory studies suggest the peptide can increase lipolysis, the breakdown of stored fat, and reduce lipogenesis, the formation of new fat. Unlike full human growth hormone, it does not appear to stimulate substantial IGF-1 production in the studies reported so far. Some evidence points to beta-adrenergic signaling, but the precise receptor targets and downstream pathways remain unresolved. The fragment is not thought to act through the classical growth hormone receptor.
==== Zonal necrosis ==== This is the most common type of drug-induced liver cell necrosis where the injury is largely confined to a particular zone of the liver lobule. It may manifest as a very high level of ALT and severe disturbance of liver function leading to acute liver failure.
The following year, Pauling published what he regarded as his most important paper, in which he first laid out the concept of hybridization of atomic orbitals and analyzed the tetravalency of the carbon atom. At Caltech, Pauling struck up a close friendship with theoretical physicist Robert Oppenheimer at the University of California, Berkeley, who spent part of his research and teaching schedule as a visitor at Caltech each year. Pauling was also affiliated with Berkeley, serving as a visiting lecturer in physics and chemistry from 1929 to 1934. Oppenheimer even gave Pauling a stunning personal collection of minerals. The two men planned to mount a joint attack on the nature of the chemical bond: apparently Oppenheimer would supply the mathematics and Pauling would interpret the results. Their relationship soured when Oppenheimer tried to pursue Pauling's wife, Ava Helen. When Pauling was at work, Oppenheimer came to their home and blurted out an invitation to Ava Helen to join him on a tryst in Mexico. She flatly refused, and reported the incident to Pauling. He immediately cut off his relationship with Oppenheimer. In the summer of 1930, Pauling made another European trip, during which he learned about gas-phase electron diffraction from Herman Francis Mark. After returning, he built an electron diffraction instrument at Caltech with a student of his, Lawrence Olin Brockway, and used it to study the molecular structure of a large number of chemical substances. Pauling introduced the concept of electronegativity in 1932.
It may be formed by directly fluorinating bromine at room temperature and is purified through distillation. It reacts violently with water and explodes on contact with flammable materials, but is a less powerful fluorinating reagent than chlorine trifluoride. It reacts vigorously with boron, carbon, silicon, arsenic, antimony, iodine, and sulfur to give fluorides, and will also convert most metals and many metal compounds to fluorides; as such, it is used to oxidise uranium to uranium hexafluoride in the nuclear power industry. Refractory oxides tend to be only partially fluorinated, but here the derivatives KBrF4 and BrF2SbF6 remain reactive. Bromine trifluoride is a useful nonaqueous ionising solvent, since it readily dissociates to form BrF2+ and BrF4− and thus conducts electricity. Bromine pentafluoride (BrF5) was first synthesised in 1930. It is produced on a large scale by direct reaction of bromine with excess fluorine at temperatures higher than 150 °C, and on a small scale by the fluorination of potassium bromide at 25 °C. It also reacts violently with water and is a very strong fluorinating agent, although chlorine trifluoride is still stronger.
State law allows for the dispensing of the drugs/chemicals for lethal injection to the state's department of corrections without a prescription. However, states are still subject to DEA regulation with respect to lethal injection drugs.
Sources: en.wikipedia.org
==== Use as adjunctive therapy ==== Doxycycline is used as an adjunctive therapy for severe acne, acute intestinal amebiasis, and chancroid. Subantimicrobial-dose doxycycline (SDD) is widely used as an adjunctive treatment to scaling and root planing for periodontitis. SDD is also used to treat skin conditions such as acne and rosacea, including ocular rosacea. In ocular rosacea, treatment period is 2 to 3 months. After discontinuation of doxycycline, recurrences may occur within three months; therefore, many studies recommend either slow tapering or treatment with a lower dose over a longer period of time.
The neuroendocrine system is an integrated system composed of neurons, glands and non-endocrine tissues, and the hormones and neurochemicals they produce and receive collectively regulate physiological or behavioral state.
=== Exogenous === The Na+/K+-ATPase can be pharmacologically modified by administering drugs exogenously. Its expression can also be modified through hormones such as triiodothyronine, a thyroid hormone. For instance, Na+/K+-ATPase found in the membrane of heart cells is an important target of cardiac glycosides (for example digoxin and ouabain), inotropic drugs used to improve heart performance by increasing its force of contraction. Muscle contraction is dependent on a 100- to 10,000-times-higher-than-resting intracellular Ca2+ concentration, which is caused by Ca2+ release from the muscle cells' sarcoplasmic reticulum. Immediately after muscle contraction, intracellular Ca2+ is quickly returned to its normal concentration by a carrier enzyme in the plasma membrane, and a calcium pump in sarcoplasmic reticulum, causing the muscle to relax. According to the Blaustein-hypothesis, this carrier enzyme (Na+/Ca2+ exchanger, NCX) uses the Na gradient generated by the Na+-K+ pump to remove Ca2+ from the intracellular space, hence slowing down the Na+-K+ pump results in a permanently elevated Ca2+ level in the muscle, which may be the mechanism of the long-term inotropic effect of cardiac glycosides such as digoxin. The problem with this hypothesis is that at pharmacological concentrations of digitalis, less than 5% of Na/K-ATPase molecules – specifically the α2 isoform in heart and arterial smooth muscle (Kd = 32 nM) – are inhibited, not enough to affect the intracellular concentration of Na+.
Group 1.7 PAH, with an estimated 0.18% prevalence, is persistent pulmonary hypertension of the newborn. This results when the circulation does not transition from fetal to newborn configuration, leaving a patent ductus arteriosus and patent foramen ovale with left to right shunting exposing the pulmonary circulation to high pressures. PAH due to persistent pulmonary hypertension of the newborn has a 7.6% mortality at 1 year. People may sometimes have PAH belonging to more than one sub-category.
=== Intellectual origins === While Nick Land is seen as the intellectual originator of contemporary accelerationism in general, the precise origins of effective accelerationism remain unclear. The earliest known reference to the movement can be traced back to a May 2022 newsletter published by four pseudonymous authors known by their X (formerly Twitter) usernames @BasedBeffJezos, @bayeslord, @zestular and @creatine_cycle. According to Émile Torres, effective accelerationism is an extension of the TESCREAL movement, being etymologically derived from effective altruism and heavily rooted in the older Silicon Valley subcultures of transhumanism and extropianism (which similarly emphasized the value of progress and resisted efforts to restrain the development of technology), alongside elements of singularitarianism, cosmism, and longtermism. It is also often considered to have emerged at least in part from the work of the Cybernetic Culture Research Unit (of which Nick Land was a leading member, alongside writers such as Mark Fisher and Sadie Plant).
Sources: en.wikipedia.org
=== Hu-SRC-scid model === The humanized severe combined immunodeficiency (SCID) mouse model, also known as the hu-SRC-scid model, has been extensively utilized in various research areas, including immunology, infectious diseases, cancer, and drug development. This model has been instrumental in studying the human immune response to xenogeneic and allogeneic decellularized biomaterials, providing valuable insights into the biocompatibility and gene expression regulation of these materials. Hu-SRC-scid mice are developed by engrafting CD34+ human hematopoietic stem cells into immunodeficient mice. The cells are obtained from human fetal liver, bone marrow or from blood derived from the umbilical cord, and engrafted via intravenous injection. The advantages of this model are that it offers multilineage development of hematopoietic cells, generation of a naïve immune system, and if engraftment is carried out by intrahepatic injection of newborn mice within 72 hours of birth, it can lead to enhanced human cell reconstitution. Nevertheless, limitations associated with the model are that it takes a minimum of 10 weeks for cell differentiation to occur, it harbors low levels of human RBCs, polymorphonuclear leukocytes, and megakaryocytes.
== Career == Townsend held various academic positions at the Medical University of South Carolina, starting as a Research Assistant Professor (2004) in the Department of Pharmaceutical Sciences. She was appointed as an associate professor in the Drug Discovery and Biomedical Sciences department in 2015 and has been serving as a Professor and acting department chair. In 2021, Townsend became the co-director of the Administrative Core for the Redox COBRE.
=== Ribosomal RNA (rRNA) sequences provide a record of the evolutionary history of all life forms === Analysis of ribosomal RNA sequences from a large number of organisms demonstrated that all extant forms of life on Earth share common structural and sequence features of the ribosomal RNA, reflecting a common ancestry. Mapping the similarities and differences among rRNA molecules from different sources provides clear and quantitative information about the phylogenetic (i.e. evolutionary) relationships among organisms. Analysis of rRNA molecules led to the identification of a third major kingdom of organisms, the archaea, in addition to the prokaryotes and eukaryotes.
Pulsatile intravenous insulin therapy, sometimes called metabolic activation therapy or cellular activation therapy, describes in a literal sense the intravenous injection of insulin in pulses versus continuous infusions. Injection of insulin in pulses mimics the physiological secretions of insulin by the pancreas into the portal vein which then drains into the liver. In healthy, non-diabetic individuals, pancreatic secretions of insulin correspond to the intake of food. The pancreas will secrete variable amounts of insulin based upon the amount of food consumed (basically speaking, the more food that is consumed, the more insulin the pancreas will secrete) among other factors. Continuous exposure to insulin and glucagon is known to decrease the hormones' metabolic effectiveness on glucose production in humans due to the body developing an increased tolerance to the hormones. Down-regulation at the cellular level may partially explain the decreased action of steady-state levels of insulin, while pulsatile hormone secretion may allow recovery of receptor affinity and numbers for insulin. Intermittent intravenous insulin administration with peaks of insulin concentrations may enhance suppression of gluconeogenesis and reduce hepatic glucose production.
Sources: en.wikipedia.org
No major medicines regulator appears to have approved AOD-9604 for human therapeutic use. It has been studied in clinical trials, but those programs did not result in a marketed drug.
It became prominent during a 2013 Australian sports investigation that examined whether it was a prohibited growth-hormone-related substance. Subsequent interpretations and list updates have varied, so current rules should be checked directly.
Published summaries generally report limited or inconsistent weight-loss effects, and complete trial data are not widely available. The studies were not sufficient to establish it as an effective obesity treatment.
No, it is a synthetic peptide fragment corresponding to a small portion of hGH. It is not the full 191-amino-acid hormone and does not reproduce all of hGH's effects.